Brigatinib for ALK-positive Metastatic Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s147499
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Osimertinib in the Treatment of Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Lung Cancer: Targets and Therapy
Oncology
2017English

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2018English

1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

New Options in the Management of Intractable ALK(+) Metastatic Non-Small-Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2014English

How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

Cancer Cell
Cancer ResearchOncologyCell Biology
2010English

P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Nivolumab in Metastatic Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy